You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 128 No. 5, May 1993 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (31)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Isolated Pelvic Perfusion for Unresectable Cancer Using a Balloon Occlusion Technique

Peter S. Turk, MD; James F. Belliveau, PhD; James W. Darnowski, PhD; Marc C. Weinberg, MD; Luke Leenen, MD, PhD; Harold J. Wanebo, MD

Arch Surg. 1993;128(5):533-539.


Abstract

• Previously irradiated recurrent pelvic malignancy is refractory to most treatment modalities. Ten patients with local recurrences (six with rectal cancer; three, anal cancer; and one, anorectal melanoma) were treated with a total of 17 courses of isolated pelvic perfusion chemotherapy (12 with multiple agents) using standard hemodialysis technology. Aortic and inferior vena caval occlusion was maintained via transfemoral balloon catheters, with a single intraoperative balloon disruption. Mean pelvic-systemic drug exposure ratios were 9.8:1 for fluorouracil, 4.8:1 for cisplatin, and 4.4:1 for mitomycin C. Results were three partial responses (two patients subsequently underwent resection) and three minor responses, all in patients with a visible tumor. Pelvic pain was relieved in six of eight symptomatic patients (mean duration, 4 months). Using limited access, this procedure produces high pelvic-systemic concentration gradients, prolonged palliation for recurrent pelvic cancers, and increased resectability in selected patients.

(Arch Surg. 1993;128:533-539)



Author Affiliations

From the Department of Surgery (Drs Turk, Leenen, and Wanebo) and the Divisions of Medical Oncology (Dr Darnowski) and Nephrology (Dr Weinberg), Roger Williams Medical Center, Brown University, and the Department of Chemistry, Providence College (Dr Belliveau), Providence, RI. Dr Turk is currently affiliated with Randolph Surgical Associates, Charlotte, NC.


Footnotes

Accepted for publication January 24, 1993.

Presented at the 73rd Annual Meeting of the New England Surgical Society, Dixville Notch, NH, September 26, 1992.

Reprint requests to Department of Surgery, Roger Williams Medical Center, 825 Chalkstone Ave, Providence, RI 02908 (Dr Wanebo).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypoxic Pelvic Perfusion With Mitomycin C Using a Simplified Balloon-Occlusion Technique in the Treatment of Patients With Unresectable Locally Recurrent Rectal Cancer
Guadagni et al.
Arch Surg 2001;136:105-112.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.